A Look Ahead: Halozyme Therapeutics's Earnings Forecast

Halozyme Therapeutics (NASDAQ:HALO) will release its quarterly earnings report on Thursday, 2024-10-31. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.98.

Investors in Halozyme Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Past Earnings Performance

In the previous earnings release, the company beat EPS by $0.13, leading to a 4.2% increase in the share price the following trading session.

Here's a look at Halozyme Therapeutics's past performance and the resulting price change:

Quarter

Q2 2024

Q1 2024

Q4 2023

Q3 2023

EPS Estimate

0.78

0.69

0.83

0.73

EPS Actual

0.91

0.79

0.82

0.75

Price Change %

4.0%

2.0%

7.000000000000001%

10.0%

Analyst Opinions on Halozyme Therapeutics

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Halozyme Therapeutics.

Analysts have given Halozyme Therapeutics a total of 12 ratings, with the consensus rating being Buy. The average one-year price target is $62.5, indicating a potential 23.42% upside.

Peer Ratings Overview

The analysis below ...